Skip to Main content Skip to Navigation
Journal articles

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry

Abstract : Objective: The impact of gender on the response and tolerance to abatacept was assessed in a large prospective cohort during 2 years of follow-up. Methods: From the 1017 patients included in the Orencia and Rheumatoid Arthritis registry, disease activity was assessed at baseline, 6, 12 and 24 months. The relationship between the European League Against Rheumatism (EULAR) response, Disease Activity Score 28 (DAS28) remission, rate of adverse events and gender was explored in multivariate analysis. Results: 990 patients, 79.3%female, with at least one follow-up visit were analysed. At baseline, women had longer disease duration, higher disease activity and more often received antitumour necrosis factor (TNF) drugs. The remission was not different between men and women during the follow-up after adjustment on age, disease duration and activity, rheumatoid factor and anti-cyclic citrullinated pyeptide (CCP) positivity, and current disease-modifying antirheumatic drugs (DMARDs), previous TNF blockers and corticosteroids use. The proportion of men and women achieving EULAR good-or-moderate response at any endpoints was similar (52.4% vs 55.5%), as well as time to achieving EULAR response (5.4+/-4.9 vs 5.6+/-5.2 months). Moderate EULAR response was more frequent in women at 6 months (OR=1.80, p=0.02) but was no longer significant at 12 or 24 months. During the follow-up, the DAS28, the tender joint count score and the patient global assessment remained higher in women (p=0.001, 0.04 and 0.06, respectively). Drug retention and safety were comparable. Conclusion: In this large daily practice cohort of established rheumatoid arthritis treated with abatacept, women achieved similar remission and EULAR response than men despite higher disease activity and tender joint count during the treatment course.
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-01666923
Contributor : Archive Ouverte Prodinra Connect in order to contact the contributor
Submitted on : Monday, May 31, 2021 - 5:15:19 PM
Last modification on : Friday, January 7, 2022 - 3:54:54 AM

File

e000515.full.pdf
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Citation

C. Nourisson, M. Soubrier, A. Mulliez, Axelle Baillet, T. Bardin, et al.. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry. RMD Open : Rheumatic & Musculoskeletal Diseases, EULAR ; BMJ, 2017, 3 (2), pp.e000515. ⟨10.1136/rmdopen-2017-000515⟩. ⟨hal-01666923⟩

Share

Metrics

Les métriques sont temporairement indisponibles